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Introduction
The development of colorectal cancer (CRC) can be a 
slow process, with early stages of disease often presenting 
with no clinical symptoms to the patient. It has been 
indicated that most CRCs are adenocarcinomas arising 
from noncancerous adenomatous polyps [1,2]. Like many 
other types of cancer, CRC has been found to have an 
associated higher incidence with increasing age. The risk 
of CRC has a marked increase in occurrence after reach-
ing 40 years of age and incidence continues to increase 
even more rapidly after this age. Overall, the risk of CRC 
doubles with each succeeding decade of age, and continues 
to rise exponentially in incidence with age [3].
Little is known about the precise biochemical mecha-
nisms responsible for the rise in CRC with aging. Many 
possible causes for this increase in CRC incidence have 
been suggested. One model of CRC progression proposed 
by Vogelstein et al. indicates that malignancy arises as a 
result of accumulation of mutations in tumor suppressor 
genes and oncogenes [4]. Indeed, the molecular profiles 
of CRC patients have been shown to differ between vari-
ous age groups of patients examined [5–7]. Whether 
patients within these various age groups have a different 
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Abstract
Previous studies have suggested that deficiencies in mismatch repair genes 
(dMMR) often occur in patients with colorectal cancer (CRC) and contribute 
to disease etiology. Here, we looked for a correlation of MMR status to disease 
outcomes from a large number of Chinese CRC patients stratified by the age 
of onset of disease. A total of 2233 CRC patients were analyzed and tissue 
biopsies of surgically removed tumors scored for MMR gene status. The patient 
distribution after classification consisted of 188 younger aged patients (20–39 years 
of age), 1024 middle aged patients (40–59 years of age), and 1020 older aged 
patients (60–85 years of age). In this analysis, the expression of four MMR 
genes was assessed by immunohistochemistry (IHC). We found that the young 
group of CRC patients with dMMR had higher overall survival (OS) than the 
young group of patients with proficient MMR (pMMR) (77% vs. 56%, P = 0.03). 
Middle- aged patients with dMMR also had higher OS than middle- aged group 
patients with pMMR (78% vs. 68%, P = 0.012). However, we found no statisti-
cal difference in OS between dMMR and pMMR status in the older group of 
patients (75% vs. 71%, P = 0.224). Finally, the middle- and older- aged group 
set of patients had higher OS than the young group of patients (69% vs. 71% 
vs. 59%, P = 0.008). These data demonstrated that the age of disease onset can 
be an important factor to help evaluate the prognosis of CRC when combined 
with the analysis of MMR status within tumor biopsied tissue.
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biological behavior including MMR activity remains 
controversial.
MMR genes correct mismatched nucleotides and inser-
tion–deletion loops (IDLs) in DNA caused by polymerase 
errors, chemical modifications, and recombination between 
heterologous DNA sequences [8]. It was previously dem-
onstrated that stage II CRC patients with dMMR have a 
better prognosis and it was indicated that some patients 
may actually be harmed by 5- FU treatment [9]. More 
recent studies have found that CRC tumors with dMMR 
were more prevalent in younger patients [10,11]. Despite 
these early findings about MMR status, there still has 
been no conclusive study to prove an association with 
overall survival (OS) for age of disease onset and MMR 
status in CRC patients.
In this study, we sought to find if difference in MMR 
status based on age could be useful to identify groups 
of patients that would have better disease outcomes. 
Following the recommendations of the EGAPP [12], we 
performed systematic immunohistochemistry (IHC) 
screening of CRC tumor tissues looking for microsatellite 
instability of patients. Here, we had access to a large 
number of Chinese CRC patients who were operated on 
to remove their primary tumors and whose tissues were 
assessed in our institute since 2011. Our findings indicate 
that the combined analysis of age of onset and MMR 
status could provide some prognostic information about 
these CRC patient outcomes.
Materials and Methods
Patients
The ethics committee of Sun Yat- sen University Cancer 
Center approved this study and informed consents for 
all patients were obtained at the beginning of the study. 
A total of 4500 patients with histologically confirmed CRC 
tumors were recruited from the Sun Yat- sen University 
cancer center between May 2011 and May 2016 for this 
study. Clinical and familial histories for each of these 
patients were reviewed. From these recruited patients, 2233 
cases were finally selected for analysis after applying strict 
exclusion criteria that included: age less than 18 years 
and older than 85 years, severe complication, multiprimary 
cancer, synchronous and metachronous CRC, family his-
tory (first- degree and second- degree relatives had any kind 
of cancer), familial adenomatous polyposis, death not due 
to tumor- related reason, and incomplete follow- up record 
were not included for study. The primary tumor location 
site was categorized as right colon if the tumor was located 
above the splenic flexure, and left colon if it was located 
at or below the splenic flexure or as from the rectum. 
The median follow- up on surviving patients was 4.3 years.
Treatment and follow- up
Stage I (T1–2 N0) and stage II (T3–4 N0) CRC patients 
without high- risk clinical features (e.g., T4 stage, bowel 
perforation or clinical bowel obstruction, inadequate 
lymph node sampling, poorly differentiated histology) 
were treated with radical surgery or endoscopic removal 
of the tumor alone. Stage II (T3–4 N0) CRC patients 
with high- risk clinical features were recommended to 
follow the capecitabine+oxaliplatin (XELODA) treatment 
regimen. Stage III (Tx N1–2) patients were designated 
to receive radical surgery and 12 cycles of adjuvant 
mFOLFOX/XELOX regimen treatment within a 6- month 
period. All stage IV (Tx Nx M1) patients received pal-
liative surgery or radical surgery. The first- line treatment 
for stage IV CRC was mFOLFOX/FOLFIRI (folinic acid+5- 
FU+irinotecan) chemotherapy regimen. Patient clinical 
responses were evaluated in accordance with the RECIST 
guidelines. After surgery, tumor recurrence was deter-
mined by physical examination, serum carcinoembryonic 
antigen (CEA) assay, or abdominal and thoracic imaging 
taken every 3–6 months for the following 3 years after 
initial therapy, then every 6 months for the next 2 years, 
and finally followed by annual checkup. In addition, Sun 
Yat- sen University cancer center has an independent 
follow- up department. The colleagues call the patients 
or the family members regularly and register the survival 
status and health condition. The cutoff date of analysis 
for inclusion in this study was May 2016.
Immunohistochemistry
Blocks of formalin- fixed, paraffin- embedded CRC adeno-
carcinoma tissue comprising an area of normal colorectal 
mucosa adjacent to the tumor were selected in each case. 
Cases with complete nuclear loss of MMR expression in 
invasive tumor cells but with retained expression in 
inflammatory cells and/or adjacent normal tissue as posi-
tive controls were considered MMR deficient. Staining 
was performed using the following primary antibodies: 
mouse anti- human mutL homolog 1 (MLH1) (dilution 
1:150, clone OTI1C1, zhongshan jiqiao, Beijing), rabbit 
anti- human mutS homolog2 (MSH2) (dilution 1:100, 
clone ZA0622, zhongshan jiqiao, Beijing, mouse anti- 
human mutS homolog 6 (MSH6) (dilution 1:150, clone 
OTI5D1, zhongshan jiqiao, Beijing), and mouse anti- 
human postmeiotic segregation increased 2 (PMS2) (dilu-
tion 1:150, clone OTI2G5, zhongshan jiqiao, Beijing). 
Whole- tissue sections were analyzed independently by two 
pathologists and were blinded to any of the patients’ 
clinical characteristics. Any discordant cases were reviewed 
by a supplementary pathologist in order to reach a con-
sensus on the tumor characterization. Illustrative 
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immunostainings of recovered CRC tumor sections are 
shown in Figure 1.
Statistical analysis
Patient data are described in frequencies (percentages) of 
cases with the given phenotype. Differences in distribu-
tions between the variables examined were assessed by 
the χ2 or the Fisher’s exact test. The primary end point 
of the study was OS, defined as the time elapsed from 
the date of surgery until the tumor- induced death of the 
patient. Surviving patients were censored on the last follow-
 up date. Median follow- up and the 95% CI were calculated 
using the reverse Kaplan–Meier method. The survival curve 
was estimated with the Kaplan–Meier method and com-
pared using the log- rank test. The score and likelihood 
ratio test P-values were used to test the statistical signifi-
cance of each covariate in the univariate and multivariable 
Cox models, respectively. All statistical tests were two- sided, 
and P-values less than or equal to 0.05 were considered 
statistically significant. Statistical analyses were performed 
using SPSS software.
Results
A total of 2001 (89.6%) of all CRC specimens examined 
showed retained expression in tumor cells for MLH1, 
MSH2, MSH6, and PMS2 proteins. In comparison, loss 
of expression in at least one of the four MMR genes was 
found to occur in 232 of 2233 patients analyzed repre-
senting a dMMR status for 10.4% of the CRC patients 
examined. The patients analyzed included 188 patients 
(8.4%) classified as young (20–39 years old), 1024 (45.9%) 
as middle- aged patients (40–59 years old), and 1020 (45.7%) 
as older- aged patients (60–85 years old). Their median 
age at diagnosis was 58 years (ranged 18–85 years). The 
patient demographics and tumor characteristics by age 
are listed in Table 1.
In addition, we found that 55.3% of the younger patient 
group were female. With regard to dMMR status, we 
found that tumors with dMMR status tended to be noticed 
in higher incidence in younger patients (13.8%) compared 
to middle- age (12.2%) and older patients (7.9%) 
(P < 0.001). In univariate analysis, the MMR status (HR: 
1.56, 95% CI: 1.18–2.06, P = 0.002) and tumor stage 
(HR: 0.19, 95% CI: 0.16–0.23, P < 0.001) showed statisti-
cal significance. However, among the variables analyzed 
in the multivariate Cox model, only tumor stage (HR: 
0.20, 95% CI: 0.17–0.24, P < 0.001) was shown to be 
significantly associated with OS regarding the age of disease 
onset. We found that gender (HR: 0.96, 95% CI: 0.82–1.11, 
P = 0.561), tumor location (HR: 0.92, 95% CI: 0.83–1.01, 
P = 0.064), and pathological differentiation (HR: 0.97, 
95% CI: 0.84–1.12, P = 0.700) showed no statistical dif-
ferences by univariate Cox analysis (P > 0.05) regarding 
the age of disease onset.
Our most important finding in this study was that we 
could find an association for dMMR status and age of 
disease onset to OS for our Chinese CRC patients exam-
ined. As part of this analysis, we found that age alone 
had associations with OS. Here, middle- and older- aged 
patients had higher OS than younger- aged grouped patients 
(69% vs. 71% vs. 59%, HR: 1.07, 95% confidence interval 
(CI): 0.91–1.25, P = 0.008). In our results, the middle- 
(69%) and older- aged (71%) patients have similar OS with 
no significant difference. However, when the middle- and 
Figure 1. Illustrative immunostainings. Positive (upper panel) and negative (lower panel) for MLH1, MSH2, MSH6, and PMS2.
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older- aged patients are compared with younger- aged 
patients (59%), statistical significance is shown. When age 
was analyzed in conjunction with MMR status, we found 
that younger CRC patients with dMMR had higher OS 
than young patients with proficient MMR (pMMR) (77% 
vs. 56%, HR: 0.42, 95% CI: 0.19–1.02, P = 0.03). Likewise, 
we found that middle- aged patients with dMMR also had 
higher OS than middle- aged patients with pMMR (78% 
vs. 68%, HR: 0.63, 95% CI: 0.43–0.92, P = 0.012). This 
association of age with dMMR did not hold for older- age 
group patients. Here, we found no statistical difference in 
OS between dMMR and pMMR status for older- aged CRC 
patients (75% vs. 71%, HR: 0.76, 95% CI: 0.48–1.20, 
P = 0.224). Patient survival plots with regard to tumor 
location and MMR status are shown in Figure 2.
Discussion
Multiple risk factors contribute to the capacity of an 
individual to develop CRC. Disturbingly, younger- aged 
patients are more likely to be diagnosed with later stage 
disease when their cancers are discovered [13]. However, 
it is unclear whether this reflects differing biology between 
young versus older patients or simply that a low rate of 
CRC screening is performed at this young age. In our 
present Chinese population- based CRC study, we looked 
to see if age and MMR status had an impact on the 
survival of these CRC patients.
It was previously reported that younger patients have 
a higher prevalence of mucinous or signet- ring types of 
carcinoma [14,15]. Yet here, in our study, we found that 
pathological differentiation showed no statistical difference 
to OS (P > 0.05). Another study demonstrating a linkage 
to age and CRC demonstrated that the age at diagnosis 
of inflammatory bowel disease was an indicator of early 
development of CRC in inflammatory bowel disease 
patients [7].
In younger patients, CRC tend to present more com-
monly as stage III or IV disease, which may reflect dif-
fering biology in younger- aged CRC patients, but could 
Table 1. Clinicopathological characteristics of the patients.
Characteristics Ages (n/%) P-value
20–39 years 
(188/8.4)
40–59 years 
(1024/45.9)
60–85 years 
(1021/45.7)
Gender <0.001
Male 84 (3.8) 599 (26.8) 633 (28.3)
Female 104 (4.7) 425 (19.0) 388 (17.4)
Location 0.228
Right colon 52 (2.3) 243 (10.9) 226 (10.1)
Left colon 59 (2.6) 323 (14.5) 358 (16.0)
Rectum 77 (3.4) 458 (20.5) 437 (19.6)
Pathology 0.095
G1 18 (0.8) 48 (2.1) 38 (1.7)
G2 152 (6.8) 919 (41.2) 931 (41.7)
G3 0 (0.0) 5 (0.2) 13 (0.6)
Mucinous 13 (0.6) 46 (2.1) 36 (1.6)
Signet- ring 5 (0.2) 6 (0.3) 3 (0.1)
Stage <0.001
I 13 (0.6) 129 (5.8) 189 (8.5)
IIA 57 (2.6) 273 (12.2) 280 (12.5)
IIB 13 (0.6) 119 (5.3) 93 (4.2)
IIC 3 (0.1) 17 (0.8) 22 (1.0)
IIIA 6 (0.3) 25 (1.1) 24 (1.1)
IIIB 30 (1.3) 209 (9.4) 213 (9.5)
IIIC 14 (0.6) 47 (2.1) 31 (1.4)
IVA 28 (1.3) 123 (5.5) 114 (5.1)
IVB 24 (1.1) 82 (3.7) 55 (2.5)
MMR status <0.001
dMMR 26 (1.2) 125 (5.6) 81 (3.6)
pMMR 162 (7.3) 899 (40.3) 940 (42.1)
Alive 0.001
Yes 111 (5.0) 707 (31.7) 726 (32.5)
No 77 (3.4) 317 (14.2) 295 (13.2)
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also be reflective of later diagnosis because of the rarity 
of this condition in that age group, and/or less surveil-
lance in general of cancers in this age group [13]. In 
concordance with this previous study, here, we also found 
that younger patients were more likely to present as stage 
IIIB or IVB disease.
The evidence is increasing to indicate that the molecular 
profiles of CRC cells can differ in various age groups of 
patients and that this will influence the given patient’s 
disease outcome and response to therapy [5–7]. It was 
reported that CRC patients above the age of 50 showed 
decreased Bax/Bcl- 2 ratios that might differentially control 
tumor cell apoptosis between the various age groups of 
patients [5]. Also, it has been shown that peripheral blood 
leukocyte (PBL) telomere length varies according to the 
age of CRC onset, perhaps impacting immune cell func-
tions differentially [6]. With regard to MMR status, a 
more recent set of studies found that dMMR was more 
Figure 2. Overall survival (OS) according to MMR status and age in colorectal carcinoma (CRC) stage I-IV.
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prevalent in younger CRC patients [10,11]. Likewise, we 
found that tumors with a dMMR status tended to be 
more prevalent in the younger group of patients (13.8%) 
versus the middle- (12.2%) or older- aged patients (7.9%) 
(P < 0.001).
MMR corrects mismatched nucleotides and insertion–
deletion loops (IDLs) in DNA caused by polymerase 
errors, chemical modifications, and recombination 
between heterologous DNA sequences [8]. It was dem-
onstrated that stage II patients with dMMR have a better 
prognosis and may actually be harmed by 5- FU treat-
ment [9]. In our study, young CRC patients with dMMR 
had higher OS than young patients with pMMR 
(P = 0.03). We also found that middle- aged patients 
with dMMR also had higher OS than middle- aged patients 
with pMMR (P = 0.012). However, we found no sta-
tistical difference in OS between dMMR and pMMR 
status in older- aged patients (P = 0.224). While not yet 
known, these differences in disease response may be 
based upon the molecular profile or epigenetics among 
these various aged patients.
Overall, the notion that age can be a significant prog-
nostic factor in CRC has been somewhat controversial. 
Various studies have reported poorer prognosis for younger 
patients with CRC [16–19]. Yet, other authors have dem-
onstrated that younger patients with CRC surgically treated 
appeared to have a higher cancer- specific survival rate 
than elderly ones [13,19,20]. In our study here, we found 
that middle- and older- aged patients had higher OS than 
young patients (P = 0.008), indicating that again there 
is some link to age and CRC patient disease response.
In conclusion, the observation that cancer- related mor-
tality did not decrease with increasing age exemplified 
that, although elderly patients have a shorter life expectancy 
based on their age and preexistent conditions, they did 
still benefit from cancer treatment. The combination of 
age and MMR was a significant predictor of overall sur-
vival in our study, reflecting the importance of optimizing 
patient beyond treatment. The potential efficacy of age- 
tailored and molecular profiled interventions as compo-
nents of personalized care clearly need to be investigated 
further in future studies.
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